MAPK-IN-9

MAPK-IN-9 (Compound PPC-15) (1-20 μM; 7 days) potently inhibits the colony-forming ability of H1975 non-small cell lung cancer cells^[1].
MAPK-IN-9 (0.1-20 μM; 24 h) inhibits the viability of H1975 non-small cell lung cancer cells, with an IC₅₀ of 1.055 μM after 24 h of treatment^[1].
MAPK-IN-9 (10 μM; 24 h) induces significant cell death in H1975 non-small cell lung cancer cells, reducing the viable cell population by more than 48%^[1].
MAPK-IN-9 (10 μM; 18 h) induces apoptotic cell death in H1975 non-small cell lung cancer cells after 18 h of treatment, as evidenced by nuclear fragmentation and an increased population of Annexin V-positive cells^[1].
MAPK-IN-9 (1-20 μM; 6-24 h) induces apoptosis in H1975, PC-9, HCC827 and A549 non-small cell lung cancer cells by downregulating MCL-1 expression and activating caspase-7, caspase-3 and PARP, which is associated with the selective inhibition of ERK phosphorylation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.